Contact – +1-276-477-5910
 Email – info@supplydemandmarketresearch.com

Home >>

Healthcare and Social Assistance

>>

North America Active Pharmaceutical Ingredients API Market


North America Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

Report code: SDMRHE1298204 | Industry: Healthcare and Social Assistance | Published On: 44008


North America active pharmaceutical ingredients (API) market is expected to grow by 5.7% annually in the forecast period and reach $101.03 billion by 2026 driven by the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.
Highlighted with 31 tables and 62 figures, this 128-page report “North America Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Synthesis, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API

Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each aforementioned country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction  8
1.1  Industry  Definition  and  Research  Scope  8
1.1.1  Industry  Definition  8
1.1.2  Research  Scope  9
1.2  Research  Methodology  12
1.2.1  Overview  of  Market  Research  Methodology  12
1.2.2  Market  Assumption  13
1.2.3  Secondary  Data  13
1.2.4  Primary  Data  13
1.2.5  Data  Filtration  and  Model  Design  15
1.2.6  Market  Size/Share  Estimation  16
1.2.7  Research  Limitations  17
1.3  Executive  Summary  18
2  Market  Overview  and  Dynamics  20
2.1  Market  Size  and  Forecast  20
2.2  Major  Growth  Drivers  21
2.3  Market  Restraints  and  Challenges  25
2.4  Emerging  Opportunities  and  Market  Trends  28
2.5  Porter’s  Fiver  Forces  Analysis  32
3  Segmentation  of  North  America  Market  by  Synthesis  36
3.1  Market  Overview  by  Synthesis  36
3.2  Synthetic  API  38
3.2.1  Branded  Synthetic  API  39
3.2.2  Generic  Synthetic  API  40
3.3  Biotech  API  41
3.3.1  Biotech  API  by  Drug  Type  42
3.3.1.1  Monoclonal  Antibodies  43
3.3.1.2  Recombinant  Proteins  44
3.3.1.3  Vaccines  45
3.3.1.4  Other  Biotech  APIs  46
3.3.2  Biotech  API  by  Customer  Base  47
3.3.2.1  Innovative  Biologic  API  48
3.3.2.2  Generic  Biosimilar  API  49
3.3.3  Biotech  API  by  Expression  Technology  50
3.3.3.1  Mammalian  Expression  51
3.3.3.2  Microbial  Expression  52
3.3.3.3  Yeast  Expression  53
3.3.3.4  Insect  Expression  54
3.3.3.5  Other  Expression  Technologies  55
3.4  HPAPI  56
3.4.1  Branded  HPAPI  57
3.4.2  Generic  HPAPI  58
4  Segmentation  of  North  America  Market  by  Manufacturing  Process  59
4.1  Market  Overview  by  Manufacturing  Process  59
4.2  Captive  Manufacturing  61
4.2.1  Branded  Captive  API  62
4.2.2  Generic  Captive  API  63
4.3  Merchant  Manufacturing  64
4.3.1  Merchant  Manufacturing  by  Drug  Type  65
4.3.1.1  Branded  Merchant  API  66
4.3.1.2  Generic  Merchant  API  67
4.3.2  Merchant  Manufacturing  by  Drug  Synthesis  68
4.3.2.1  Merchant  Synthetic  API  69
4.3.2.2  Merchant  Biotech  API  70
5  Segmentation  of  North  America  Market  by  Therapeutic  Application  71
5.1  Market  Overview  by  Therapeutic  Application  71
5.2  Infectious  Diseases  73
5.3  Oncology  74
5.4  Ophthalmology  75
5.5  Cardiovascular  Disorders  76
5.6  Central  Nervous  System  77
5.7  Pulmonary  Disorders  78
5.8  Orthopedics  79
5.9  Other  Applications  80
6  Segmentation  of  North  America  Market  by  Drug  Type  81
6.1  Market  Overview  by  Drug  Type  81
6.2  Branded  Prescription  Drugs  83
6.3  Generic  Prescription  Drugs  84
6.4  OTC  Drugs  85
7  North  America  Market  2019-2026  by  Country  86
7.1  Overview  of  North  America  Market  86
7.2  U.S.  89
7.3  Canada  93
7.4  Mexico  95
8  Competitive  Landscape  97
8.1  Overview  of  Key  Vendors  97
8.2  New  Product  Launch,  Partnership,  Investment,  and  M&A  100
8.3  Company  Profiles  101
AbbVie  Inc.  101
Astrazeneca  103
Aurobindo  Pharma  Ltd.  104
Bayer  Healthcare  105
Bioniche  Animal  Health  106
Boehringer  Ingelheim  107
Bristol-Myers  Squibb  108
Ceva  Animal  Health,  Inc.  109
Elanco  Animal  Health  110
Eli  Lilly  and  Company  111
F.  Hoffmann-La  Roche  112
Glaxosmithkline  PLC  113
Heska  Co.  114
Lonza  Group  115
Merck  &  Co.,  Inc.  116
Novartis  International  AG  117
Pfizer,  Inc.  118
Ranbaxy  Laboratories  119
Sanofi  120
Sun  Pharmaceutical  Industries  Ltd.  121
9  Investing  in  North  America  Market:  Risk  Assessment  and  Management  122
9.1  Risk  Evaluation  of  North  America  Market  122
9.2  Critical  Success  Factors  (CSFs)  125
Related  Reports  and  Products  128
Table 1. Snapshot of North America Active Pharmaceutical Ingredients (API) Market, 2019-2026 19
Table 2. Main Product Trends and Market Opportunities in North America Active Pharmaceutical Ingredients (API) Market 28
Table 3. North America Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 36
Table 4. North America Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2015-2026, $ bn 38
Table 5. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2015-2026, $ bn 42
Table 6. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2015-2026, $ bn 47
Table 7. North America Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2015-2026, $ bn 50
Table 8. North America Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2015-2026, $ bn 56
Table 9. North America Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 59
Table 10. North America Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2015-2026, $ bn 61
Table 11. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2015-2026, $ bn 65
Table 12. North America Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2015-2026, $ bn 68
Table 13. North America Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 71
Table 14. North America Active Pharmaceutical Ingredients (API) Market by Drug Type, 2015-2026, $ bn 81
Table 15. North America Active Pharmaceutical Ingredients (API) Market by Country, 2015-2026, $ bn 87
Table 16. U.S. Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 91
Table 17. U.S. Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 91
Table 18. U.S. Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 91
Table 19. Canada Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 94
Table 20. Canada Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 94
Table 21. Canada Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 94
Table 22. Mexico Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 96
Table 23. Mexico Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 96
Table 24. Mexico Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 96
Table 25. AbbVie Inc.: Company Snapshot 101
Table 26. AbbVie Inc.: Business Segmentation 101
Table 27. AbbVie Inc.: Product Portfolio 102
Table 28. AbbVie Inc.: Revenue, 2016-2018, $ bn 102
Table 29. AbbVie Inc.: Recent Developments 102
Table 30. Risk Evaluation for Investing in North America Market, 2019-2026 123
Table 31. Critical Success Factors and Key Takeaways 126
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT